Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: a population-based study.
astrocytoma
glioblastoma
mortality
pediatric
socioeconomic
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
16
6
2020
pubmed:
17
6
2020
medline:
17
6
2020
Statut:
ppublish
Résumé
We assessed glioma incidence and disparities in postglioma survival rate in the Olmsted County, Minnesota, population. This population-based study assessed the incidence of pathologically confirmed primary gliomas between January 1, 1995, and December 31, 2014. Age- and sex-adjusted incidence rates per 100 000 person-years were calculated and standardized to the US white 2010 population. We compared incidence trends of glioma during our study period with previously published Olmsted County data from 1950 to 1990. We assessed postglioma survival rates among individuals with different socioeconomic status (SES), which was measured by a validated individual HOUsing-based SES index (HOUSES). We identified 135 incident glioma cases (93% white) with 20 pediatric (50% female) and 115 adult cases (44% female). Overall incidence rate during our study period, 5.51 per 100 000 person-years (95% CI: 4.56-6.46), showed no significant changes and was similar to that seen in 1950 to 1990, 5.5 per 100 000 person-years. The incidence of pediatric (age < 20 years) glioma was 2.49 (95% CI: 1.40-3.58), whereas adult glioma incidence was 6.47 (95% CI: 5.26-7.67). Among those with grade II to IV gliomas, individuals with lower SES (< median HOUSES) had significantly lower 5-year survival rates compared to those with higher SES, adjusted hazard ratio 1.61 (95% CI: 1.01-2.85). In a well-defined North American population, long-term glioma incidence appears stable since 1950. Significant socioeconomic disparities exist for postglioma survival.
Sections du résumé
BACKGROUND
BACKGROUND
We assessed glioma incidence and disparities in postglioma survival rate in the Olmsted County, Minnesota, population.
METHODS
METHODS
This population-based study assessed the incidence of pathologically confirmed primary gliomas between January 1, 1995, and December 31, 2014. Age- and sex-adjusted incidence rates per 100 000 person-years were calculated and standardized to the US white 2010 population. We compared incidence trends of glioma during our study period with previously published Olmsted County data from 1950 to 1990. We assessed postglioma survival rates among individuals with different socioeconomic status (SES), which was measured by a validated individual HOUsing-based SES index (HOUSES).
RESULTS
RESULTS
We identified 135 incident glioma cases (93% white) with 20 pediatric (50% female) and 115 adult cases (44% female). Overall incidence rate during our study period, 5.51 per 100 000 person-years (95% CI: 4.56-6.46), showed no significant changes and was similar to that seen in 1950 to 1990, 5.5 per 100 000 person-years. The incidence of pediatric (age < 20 years) glioma was 2.49 (95% CI: 1.40-3.58), whereas adult glioma incidence was 6.47 (95% CI: 5.26-7.67). Among those with grade II to IV gliomas, individuals with lower SES (< median HOUSES) had significantly lower 5-year survival rates compared to those with higher SES, adjusted hazard ratio 1.61 (95% CI: 1.01-2.85).
CONCLUSION
CONCLUSIONS
In a well-defined North American population, long-term glioma incidence appears stable since 1950. Significant socioeconomic disparities exist for postglioma survival.
Identifiants
pubmed: 32537178
doi: 10.1093/nop/npz065
pii: npz065
pmc: PMC7274190
doi:
Types de publication
Journal Article
Langues
eng
Pagination
288-298Subventions
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126667
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Clin Neurosci. 2013 Jun;20(6):783-9
pubmed: 23639619
Cancer. 2015 Jan 1;121(1):102-12
pubmed: 25155924
BMJ Open. 2015 Apr 29;5(4):e006469
pubmed: 25926142
Mayo Clin Proc. 2016 May;91(5):612-22
pubmed: 27068669
J Clin Neurosci. 2013 Oct;20(10):1362-5
pubmed: 23769599
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
BMJ Open. 2018 May 14;8(5):e020054
pubmed: 29764878
BMC Public Health. 2016 Sep 21;16(1):1000
pubmed: 27655468
Soc Sci Med. 2003 Feb;56(4):769-84
pubmed: 12560010
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Cancer Med. 2018 Oct;7(10):5281-5290
pubmed: 30175510
Ann N Y Acad Sci. 1982;381:6-16
pubmed: 6953802
NPJ Prim Care Respir Med. 2014 Jun 26;24:14018
pubmed: 24965967
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
PLoS One. 2017 May 4;12(5):e0175136
pubmed: 28472042
Cancer. 2004 Nov 15;101(10):2293-9
pubmed: 15476282
J Neurooncol. 2017 May;132(3):447-453
pubmed: 28258423
Ann Epidemiol. 2016 Jul;26(7):455-460
pubmed: 27266369
Mayo Clin Proc. 2012 Dec;87(12):1202-13
pubmed: 23199802
J Neurosurg. 2000 Dec;93(6):932-9
pubmed: 11117865
Ann Epidemiol. 2017 Jul;27(7):415-420.e2
pubmed: 28648550
J Urban Health. 2011 Oct;88(5):933-44
pubmed: 21499815
Cancer. 2019 Oct 1;125(19):3390-3400
pubmed: 31206646
Neuroepidemiology. 2008;30(1):34-44
pubmed: 18259099
J Neurooncol. 2017 May;133(1):17-25
pubmed: 28397028
Epidemiol Infect. 2013 Apr;141(4):880-7
pubmed: 22874665
Int J Environ Res Public Health. 2014 Nov 12;11(11):11597-615
pubmed: 25396769
N Engl J Med. 2007 Apr 12;356(15):1527-35
pubmed: 17429084
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Acta Oncol. 2006;45(3):272-9
pubmed: 16644569
J Clin Neurosci. 2010 Sep;17(9):1144-7
pubmed: 20576437
Cancer. 2005 Dec 15;104(12):2798-806
pubmed: 16288487
Asia Pac J Clin Oncol. 2014 Jun;10(2):153-61
pubmed: 23701649
Am J Public Health. 2008 Sep;98(9):1608-15
pubmed: 18633099
J Epidemiol Community Health. 2016 Mar;70(3):286-91
pubmed: 26458399
Ann Neurol. 1995 Jan;37(1):67-73
pubmed: 7818260
Neuro Oncol. 2014 Jul;16(7):971-4
pubmed: 24470555
J Neurol Neurosurg Psychiatry. 1996 Aug;61(2):143-50
pubmed: 8708681
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
J Allergy Clin Immunol. 2016 May;137(5):1406-12
pubmed: 26739414
J Neurosurg. 1958 Nov;15(6):627-41
pubmed: 13599054